Jacob Bush

Jacob Bush is a Director in Chemical Biology at GSK and heads the Covalent Fragment Drug Discovery platforms. He leads a Crick-GSK collaboration to develop a covalent chemoproteomics platform to unlock undruggable targets, with the intention of forming a GSK:Crick joint venture spin-out company. Jacob will serve as Founding Director of the Crick:GSK joint venture, transitioning to Founding CEO/CSO. Jacob has a PhD in Chemical Biology from Oxford and has published over 40 scientific papers.